- Simtra BioPharma Solutions announces a $250+ million expansion of its sterile fill/finish manufacturing campus in Bloomington, Indiana.
- The construction of the new building is planned to begin in June 2024 and anticipated to take two years to complete.
Simtra BioPharma Solutions, a injectable contract development and manufacturing organisation (CDMO), has announced a $250+ million expansion of its sterile fill/finish manufacturing campus in Bloomington, Indiana.
A new, state-of-the-art 150,000 square foot building will be constructed to house two high-speed automated isolator syringe fill lines and a new high-speed isolator vial line equipped with three 30 square meter lyophilisers. Each process suite in the new building will be fitted with dedicated formulation/compounding rooms.
The expansion will also include the addition of a dedicated clinical line equipped to support our growing development/clinical business. This line will utilise existing facility infrastructure. The clinical line is expected to be ready to onboard new projects by summer 2025.
Construction of the new building is planned to begin in June 2024 and anticipated to take two years to complete, allowing for GMP readiness in late 2026.
“We are experiencing a broad increase in demand and need for injectable manufacturing in therapeutic classes such as GLP-1 drugs and product categories such Antibody-Drug-Conjugates as well as overall continued growth of the oncology pipeline,” said Franco Negron, CEO of Simtra BioPharma Solutions.
“Our customers consider our sites in Halle and Bloomington as an extension of their manufacturing network, so we are thrilled to further enhance our capabilities and resources to help them meet their respective goals. This expansion is the latest in a series of strategic, long-term investments to ensure that Simtra continues to grow with and for our customers.”
Overview of outsourcing trends 
